The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there is a big study that's going to come out should finish a year from now called strength that is bigger than reduce it and using the same doses reduce it but it's epa plus dha what dose approximately so that would be four grams total
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
the drug is called empanada or EEP anova it's from AstraZeneca it's the 13,000 patient trial virtually the same inclusion criteria as reduce it that'll be about a five-year follow-up the same as reduce it and they are gonna I'm pretty sure they're gonna get much higher omega-3 index levels then reduce it did and again their drug is four grams EPA plus some amount of DHA or four grams total